OSE Immunotherapeutics has several partnerships with clinical organizations to leverage their expertise
The oncology cooperative group GERCOR, a network of 300 cancer centers in France dedicated to clinical trials in solid cancers, sponsor the ongoing Phase 2 clinical trial (TEDOPaM) evaluating TEDOPI® in pancreatic cancer.
As part of the European Network for Gynecological Oncology Trial Groups (ENGOT), the oncology cooperative group ARCAGY-GINECO is sponsor of the ongoing Phase 2 clinical trial (TEDOVA) evaluating Tedopi® in combination with pembrolizumab (Keytruda®) in ovarian cancer.
The Italian oncology Foundation FoRT is sponsor of the ongoing Phase 2 clinical trial evaluating Tedopi® in combination with nivolumab (Opdivo®) in second-line treatment in metastatic non-small cell lung cancer, after a first line of chemo-immunotherapy.
Nantes University Hospital
The Nantes University Hospital sponsors the ongoing Phase 1/2 clinical trial evaluating first administration of FR104 in patients undergoing a renal transplant.